Feb 27, 2012 | |
Nanostart Holding Lumiphore Announces European Launch of Diagnostic Tests |
|
(Nanowerk News) Nanostart holding Lumiphore announced the European launch of three diagnostic tests by its partner ThermoFisher Scientific Clinical Diagnostics using Lumiphore's time-resolved fluorescent reporter technology. ThermoFisher Clinical Diagnostics has launched three CE-marked in vitro diagnostic tests in countries of the European Economic Area (EEA), consisting of the 27 Member States of the EU and EFTA countries, Iceland, Norway, Switzerland, and Liechtenstein. | |
The tests are assays produced by Brahms with the designations Copeptin us KRYPTOR, CT-proAVP KRYPTOR, and TRAK human KRYPTOR. Since June 2009, Brahms has been a contractual partner of Lumiphore. The company was acquired by ThermoFisher in September 2009. | |
These diagnostic tests use Lumiphore's Lumi4® technology, a new class of fluorescent-metal lanthanide detection reagents patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley. | |
"Using Lumi4®-Tb will not only potentially increase sensitivity of certain BRAHMS diagnostic tests, but we are hopeful BRAHMS will consider the development of multiplexed assays – measuring 3-4 parameters in one test sample," explained Dr. Steven Blose, Lumiphore's chief business officer. The impact of multiplexing – multiple diagnostic tests in one sample – on the daily clinical routine spares patients the burden of repeated blood withdrawal, while simultaneously saving time and expense for hospitals. | |
About Nanostart | |
Nanostart AG headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. | |
About Lumiphore | |
Based in Richmond, California, Lumiphore Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications, which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, visit www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc. |
Source: Nanostart (press release) |
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: